$ALDX
Aldeyra Therapeutics, Inc.

2017 Q4 Form 10-Q Financial Statement

#000119312517338853 Filed on November 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.500M $1.480M $1.400M
YoY Change 23.97% 5.71% 11.11%
% of Gross Profit
Research & Development $5.550M $3.539M $3.380M
YoY Change 60.87% 4.72% 62.77%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $7.050M $3.539M $3.380M
YoY Change 51.61% 4.72% 62.77%
Operating Profit -$5.015M -$4.776M
YoY Change 5.0% 43.11%
Interest Expense $90.00K $27.58K $26.65K
YoY Change 3.47% -5.08%
% of Operating Profit
Other Income/Expense, Net $29.07K $1.138K
YoY Change 2454.75% -104.05%
Pretax Income -$6.950M -$4.990M -$4.780M
YoY Change 49.46% 4.39% 41.84%
Income Tax
% Of Pretax Income
Net Earnings -$6.950M -$4.986M -$4.775M
YoY Change 49.46% 4.42% 41.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$362.9K -$320.3K -$383.3K
COMMON SHARES
Basic Shares Outstanding 19.12M shares 15.15M shares 12.47M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.90M $47.90M $28.90M
YoY Change 72.29% 65.74% -5.56%
Cash & Equivalents $20.02M $33.10M $14.57M
Short-Term Investments $22.90M $14.80M $14.30M
Other Short-Term Assets $1.000M $1.100M $300.0K
YoY Change 400.0% 266.67% -50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $43.97M $49.05M $29.13M
YoY Change 74.94% 68.42% -6.72%
LONG-TERM ASSETS
Property, Plant & Equipment $43.26K $38.02K $65.69K
YoY Change -23.23% -42.13% -25.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $100.0K $0.00
YoY Change
Total Long-Term Assets $209.2K $176.7K $65.69K
YoY Change 271.22% 168.96% -47.32%
TOTAL ASSETS
Total Short-Term Assets $43.97M $49.05M $29.13M
Total Long-Term Assets $209.2K $176.7K $65.69K
Total Assets $44.17M $49.23M $29.19M
YoY Change 75.38% 68.64% -6.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.001M $485.3K $733.6K
YoY Change 263.4% -33.85% -1.35%
Accrued Expenses $2.236M $1.507M $1.477M
YoY Change 14.91% 2.09% 134.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $116.3K $426.5K $426.5K
YoY Change 50.0% 0.0%
Total Short-Term Liabilities $3.354M $2.419M $2.637M
YoY Change 45.86% -8.25% 91.9%
LONG-TERM LIABILITIES
Long-Term Debt $1.220M $905.3K $883.3K
YoY Change -1.49% 2.49% -31.05%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.220M $905.3K $883.3K
YoY Change -1.49% 2.49% -31.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.354M $2.419M $2.637M
Total Long-Term Liabilities $1.220M $905.3K $883.3K
Total Liabilities $4.574M $3.324M $3.520M
YoY Change 29.29% -5.55% 32.58%
SHAREHOLDERS EQUITY
Retained Earnings -$99.64M -$92.69M -$72.65M
YoY Change 28.9% 27.58% 33.93%
Common Stock $139.3M $138.6M $98.31M
YoY Change 40.74% 40.97% 18.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $39.60M $45.90M $25.67M
YoY Change
Total Liabilities & Shareholders Equity $44.17M $49.23M $29.19M
YoY Change 75.38% 68.64% -6.89%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$6.950M -$4.986M -$4.775M
YoY Change 49.46% 4.42% 41.88%
Depreciation, Depletion And Amortization $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$5.020M -$4.700M -$3.510M
YoY Change 28.39% 33.9% 21.88%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$8.090M -$3.630M $570.0K
YoY Change -712.88% -736.84%
Cash From Investing Activities -$8.110M -$3.630M $560.0K
YoY Change -714.39% -748.21% -1033.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $26.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K 26.83M -100.0K
YoY Change 25.0% -26930.0% 900.0%
NET CHANGE
Cash From Operating Activities -5.020M -4.700M -3.510M
Cash From Investing Activities -8.110M -3.630M 560.0K
Cash From Financing Activities 50.00K 26.83M -100.0K
Net Change In Cash -13.08M 18.50M -3.050M
YoY Change 412.94% -706.56% 3.39%
FREE CASH FLOW
Cash From Operating Activities -$5.020M -$4.700M -$3.510M
Capital Expenditures -$10.00K $0.00 $0.00
Free Cash Flow -$5.010M -$4.700M -$3.510M
YoY Change 28.13% 33.9% 24.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
14807166
CY2017Q3 us-gaap Assets
Assets
49229420
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1002
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19117676 shares
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14568508
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1507458
CY2017Q3 us-gaap Assets Current
AssetsCurrent
49052742
CY2017Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
46866598
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
138574234
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
485267
CY2017Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
34810681
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33103849
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19117676 shares
CY2017Q3 us-gaap Cash
Cash
1044417
CY2017Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.52
CY2017Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1384608 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19117676 shares
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
19118
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
645871
CY2017Q3 us-gaap Liabilities
Liabilities
3324483
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49229420
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2419230
CY2017Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2017Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
426505
CY2017Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
905253
CY2017Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
12056919
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1141727
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Assets Current
AssetsCurrent
25131327
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
24517796
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
98938446
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
275441
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
129
CY2016Q4 us-gaap Assets
Assets
25187679
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38017
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92687413
CY2017Q3 us-gaap Securities For Reverse Repurchase Agreements
SecuritiesForReverseRepurchaseAgreements
19500000
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3205195
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5438617
CY2017Q3 us-gaap Share Price
SharePrice
7.20
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1072576 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.37
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2236857 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.87
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
45904937
CY2017Q3 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
15310681
CY2017Q3 aldx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
138661
CY2017Q3 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
680637
CY2017Q3 aldx Fair Value Of Warrant Issued
FairValueOfWarrantIssued
266000
CY2017Q3 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
180950
CY2017Q3 aldx Class Of Warrant Or Right Issued And Expired
ClassOfWarrantOrRightIssuedAndExpired
0 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14648866
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1946251
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
12897584
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12015061
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12576325 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12576325 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
12576
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
983449
CY2016Q4 us-gaap Liabilities
Liabilities
3537862
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25187679
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2299238
CY2016Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
77546
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1238624
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
dei Amendment Flag
AmendmentFlag
false
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
218682
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56352
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77301334
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2186398
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1498585 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.63
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
21649817
CY2016Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
913838
CY2016Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
48964
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
20931
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2159714
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3066186 shares
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-182963
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-80358
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14033132
us-gaap Depreciation
Depreciation
26454
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.28
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4314483
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
290163
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-117600
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-247346
us-gaap Interest Expense
InterestExpense
79507
us-gaap Investment Income Interest
InvestmentIncomeInterest
74463
us-gaap Interest Paid
InterestPaid
58722
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1545181
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11238050
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12702873
us-gaap Net Income Loss
NetIncomeLoss
-14048021
us-gaap Operating Income Loss
OperatingIncomeLoss
-14042977
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5044
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
14889
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14889
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
15378371
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11810
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12702873
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13845000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9728494
us-gaap Share Based Compensation
ShareBasedCompensation
2159714
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10942127 shares
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
15588
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2122669
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3778593 shares
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-165562
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
21088788
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15387218
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation
Depreciation
29927
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.04
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001341235
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4684574
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-438793
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
209826
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
923045
us-gaap Interest Expense
InterestExpense
80878
us-gaap Investment Income Interest
InvestmentIncomeInterest
136652
us-gaap Interest Paid
InterestPaid
64024
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>NATURE OF BUSINESS</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra), a Delaware corporation, is developing new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and <font style="WHITE-SPACE: nowrap">pro-inflammatory</font> mediators known as aldehydes.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company&#x2019;s principal activities to date include raising capital and research and development activities.</p> </div>
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2087867
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14204345
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37381000
us-gaap Net Income Loss
NetIncomeLoss
-15386079
us-gaap Operating Income Loss
OperatingIncomeLoss
-15441853
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
55774
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1131
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1131
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
20198275
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11592
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37474106
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
45555
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
18122000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10757279
us-gaap Share Based Compensation
ShareBasedCompensation
2122669
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y0M18D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
151065 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.00 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.02
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
889337 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
dei Trading Symbol
TradingSymbol
ALDX
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14844914 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates and assumptions.</p> </div>
aldx Class Of Warrants Or Right Exercised
ClassOfWarrantsOrRightExercised
0
aldx Number Of Incentive Plans
NumberOfIncentivePlans
3 Incentive_Plan
aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
aldx Deferred Offering Costs Paid In Cash
DeferredOfferingCostsPaidInCash
138661
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10600000
aldx Class Of Warrant Or Right Weighted Average Remaining Life Of Warrant Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingLifeOfWarrantOrRights
P3M19D
CY2017Q1 us-gaap Sale Of Stock Transaction Date
SaleOfStockTransactionDate
2017-02-28
CY2017Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26900000
CY2017Q3 us-gaap Sale Of Stock Transaction Date
SaleOfStockTransactionDate
2017-09-30
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M10D
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
877025
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3066186 shares
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4773482
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1396734
CY2016Q3 us-gaap Interest Expense
InterestExpense
26654
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
27792
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-4775307
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4776445
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1138
CY2016Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1825
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1825
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3379711
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12474609 shares
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
659339
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3778593 shares
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4982561
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1475904
CY2017Q3 us-gaap Interest Expense
InterestExpense
27578
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
56651
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-4986199
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5015272
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29073
CY2017Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3638
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3638
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3539368
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15581426 shares

Files In Submission

Name View Source Status
0001193125-17-338853-index-headers.html Edgar Link pending
0001193125-17-338853-index.html Edgar Link pending
0001193125-17-338853.txt Edgar Link pending
0001193125-17-338853-xbrl.zip Edgar Link pending
aldx-20170930.xml Edgar Link completed
aldx-20170930.xsd Edgar Link pending
aldx-20170930_cal.xml Edgar Link unprocessable
aldx-20170930_def.xml Edgar Link unprocessable
aldx-20170930_lab.xml Edgar Link unprocessable
aldx-20170930_pre.xml Edgar Link unprocessable
d656262d10q.htm Edgar Link pending
d656262dex1027.htm Edgar Link pending
d656262dex311.htm Edgar Link pending
d656262dex312.htm Edgar Link pending
d656262dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g656262page48.jpg Edgar Link pending
g656262page58.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending